Aquarius Surgical Technologies Inc. Logo

Aquarius Surgical Technologies Inc.

ASTI.CN

(1.8)
Stock Price

0,02 CAD

-111.44% ROA

15.58% ROE

-0.19x PER

Market Cap.

137.996,00 CAD

-89.77% DER

0% Yield

-309.33% NPM

Aquarius Surgical Technologies Inc. Stock Analysis

Aquarius Surgical Technologies Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Aquarius Surgical Technologies Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (19.55%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0.03x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-89%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 ROA

The stock's ROA (-114.77%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Aquarius Surgical Technologies Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Aquarius Surgical Technologies Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Aquarius Surgical Technologies Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Aquarius Surgical Technologies Inc. Revenue
Year Revenue Growth
1996 1.800.000
1997 4.400.000 59.09%
1998 3.100.000 -41.94%
1999 1.400.000 -121.43%
2000 461.351 -203.46%
2001 424.663 -8.64%
2002 241.650 -75.73%
2003 312.412 22.65%
2004 257.551 -21.3%
2005 252.227 -2.11%
2006 282.717 10.78%
2007 258.371 -9.42%
2008 214.573 -20.41%
2009 236.248 9.17%
2010 302.331 21.86%
2011 277.470 -8.96%
2012 184.946 -50.03%
2013 205.905 10.18%
2014 0 0%
2015 0 0%
2016 5.895 100%
2017 974.538 99.4%
2018 393.385 -147.73%
2019 958.743 58.97%
2020 583.444 -64.32%
2021 327.662 -78.06%
2022 203.733 -60.83%
2023 246.744 17.43%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Aquarius Surgical Technologies Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Aquarius Surgical Technologies Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 843.216 100%
2017 1.538.886 45.21%
2018 1.417.215 -8.59%
2019 1.562.035 9.27%
2020 873.778 -78.77%
2021 766.617 -13.98%
2022 464.875 -64.91%
2023 373.988 -24.3%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Aquarius Surgical Technologies Inc. EBITDA
Year EBITDA Growth
1996 -1.500.000
1997 -600.000 -150%
1998 -900.000 33.33%
1999 -1.100.000 18.18%
2000 -1.154.652 4.73%
2001 -532.313 -116.91%
2002 -279.580 -90.4%
2003 -268.778 -4.02%
2004 -311.154 13.62%
2005 -394.189 21.06%
2006 -389.176 -1.29%
2007 -402.018 3.19%
2008 -379.887 -5.83%
2009 -351.456 -8.09%
2010 -253.347 -38.73%
2011 -235.567 -7.55%
2012 -271.368 13.19%
2013 -265.782 -2.1%
2014 -32.018 -730.1%
2015 -44.882 28.66%
2016 -843.005 94.68%
2017 -1.425.228 40.85%
2018 -1.243.166 -14.65%
2019 -1.169.262 -6.32%
2020 375.208 411.63%
2021 -636.765 158.92%
2022 -656.660 3.03%
2023 -534.764 -22.79%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Aquarius Surgical Technologies Inc. Gross Profit
Year Gross Profit Growth
1996 400.000
1997 1.600.000 75%
1998 700.000 -128.57%
1999 0 0%
2000 -339.140 100%
2001 -75.931 -346.64%
2002 24.731 407.03%
2003 80.062 69.11%
2004 76.073 -5.24%
2005 69.926 -8.79%
2006 78.742 11.2%
2007 79.461 0.9%
2008 69.867 -13.73%
2009 78.441 10.93%
2010 104.151 24.69%
2011 83.579 -24.61%
2012 65.086 -28.41%
2013 47.762 -36.27%
2014 0 0%
2015 0 0%
2016 211 100%
2017 111.066 99.81%
2018 161.408 31.19%
2019 378.251 57.33%
2020 216.595 -74.64%
2021 130.297 -66.23%
2022 81.912 -59.07%
2023 218.156 62.45%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Aquarius Surgical Technologies Inc. Net Profit
Year Net Profit Growth
1996 -1.800.000
1997 -2.400.000 25%
1998 -1.100.000 -118.18%
1999 -1.400.000 21.43%
2000 -1.220.799 -14.68%
2001 -793.346 -53.88%
2002 -218.386 -263.28%
2003 -773.444 71.76%
2004 -346.270 -123.36%
2005 -311.145 -11.29%
2006 -96.599 -222.1%
2007 -336.221 71.27%
2008 -405.186 17.02%
2009 -377.015 -7.47%
2010 -244.439 -54.24%
2011 -275.759 11.36%
2012 -288.845 4.53%
2013 183.723 257.22%
2014 -241.472 176.08%
2015 162.530 248.57%
2016 -876.308 118.55%
2017 -6.251.890 85.98%
2018 -1.586.709 -294.02%
2019 -1.610.649 1.49%
2020 -2.828.036 43.05%
2021 -831.859 -239.97%
2022 -723.440 -14.99%
2023 -670.124 -7.96%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Aquarius Surgical Technologies Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 -2
1997 -1 0%
1998 -1 0%
1999 -1 0%
2000 -1 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Aquarius Surgical Technologies Inc. Free Cashflow
Year Free Cashflow Growth
1996 -1.300.000
1997 -2.100.000 38.1%
1998 -1.000.000 -110%
1999 -900.000 -11.11%
2000 -155.704 -478.02%
2001 -673.373 76.88%
2002 -469.445 -43.44%
2003 -307.773 -52.53%
2004 -342.360 10.1%
2005 -426.764 19.78%
2006 -398.724 -7.03%
2007 -431.895 7.68%
2008 -444.923 2.93%
2009 -322.056 -38.15%
2010 -219.924 -46.44%
2011 -220.185 0.12%
2012 -300.112 26.63%
2013 -218.671 -37.24%
2014 -248.269 11.92%
2015 -34.530 -619%
2016 -350.745 90.16%
2017 -1.645.862 78.69%
2018 -2.170.051 24.16%
2019 -1.074.238 -102.01%
2020 -509.003 -111.05%
2021 -114.064 -346.24%
2022 71.825 258.81%
2023 -85.348 184.16%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Aquarius Surgical Technologies Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 -1.300.000
1997 -1.600.000 18.75%
1998 -1.000.000 -60%
1999 -900.000 -11.11%
2000 -155.281 -479.59%
2001 -673.373 76.94%
2002 -469.445 -43.44%
2003 -306.573 -53.13%
2004 -339.798 9.78%
2005 -426.764 20.38%
2006 -396.024 -7.76%
2007 -431.295 8.18%
2008 -444.923 3.06%
2009 -318.359 -39.76%
2010 -218.013 -46.03%
2011 -220.185 0.99%
2012 -297.512 25.99%
2013 -218.671 -36.05%
2014 -248.269 11.92%
2015 -34.530 -619%
2016 -325.497 89.39%
2017 -1.612.334 79.81%
2018 -1.351.504 -19.3%
2019 -951.175 -42.09%
2020 -409.003 -132.56%
2021 -108.843 -275.77%
2022 77.046 241.27%
2023 -85.348 190.27%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Aquarius Surgical Technologies Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 0
1997 500.000 100%
1998 0 0%
1999 0 0%
2000 423 100%
2001 0 0%
2002 0 0%
2003 1.200 100%
2004 2.562 53.16%
2005 0 0%
2006 2.700 100%
2007 600 -350%
2008 0 0%
2009 3.697 100%
2010 1.911 -93.46%
2011 0 0%
2012 2.600 100%
2013 0 0%
2014 0 0%
2015 0 0%
2016 25.248 100%
2017 33.528 24.7%
2018 818.547 95.9%
2019 123.063 -565.14%
2020 100.000 -23.06%
2021 5.221 -1815.34%
2022 5.221 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Aquarius Surgical Technologies Inc. Equity
Year Equity Growth
1996 -1.100.000
1997 -3.500.000 68.57%
1998 -4.700.000 25.53%
1999 -6.100.000 22.95%
2000 -7.290.144 16.33%
2001 -2.395.257 -204.36%
2002 -2.613.643 8.36%
2003 -2.887.087 9.47%
2004 -3.233.357 10.71%
2005 -1.944.502 -66.28%
2006 -2.041.101 4.73%
2007 -2.377.322 14.14%
2008 -2.782.508 14.56%
2009 -3.159.523 11.93%
2010 -3.403.962 7.18%
2011 -3.567.551 4.59%
2012 -3.856.295 7.49%
2013 -3.672.572 -5%
2014 -3.914.044 6.17%
2015 -3.863.785 -1.3%
2016 5.017.644 177%
2017 128.688 -3799.08%
2018 -453.896 128.35%
2019 -689.155 34.14%
2020 -2.394.660 71.22%
2021 -3.214.856 25.51%
2022 -3.847.896 16.45%
2023 -4.201.385 8.41%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Aquarius Surgical Technologies Inc. Assets
Year Assets Growth
1996 1.800.000
1997 2.100.000 14.29%
1998 1.600.000 -31.25%
1999 1.100.000 -45.45%
2000 693.332 -58.65%
2001 447.138 -55.06%
2002 165.199 -170.67%
2003 156.448 -5.59%
2004 131.857 -18.65%
2005 157.465 16.26%
2006 147.604 -6.68%
2007 157.701 6.4%
2008 181.067 12.9%
2009 182.794 0.94%
2010 170.141 -7.44%
2011 236.899 28.18%
2012 248.502 4.67%
2013 210.970 -17.79%
2014 141.366 -49.24%
2015 12.688 -1014.17%
2016 8.399.160 99.85%
2017 1.612.203 -420.97%
2018 1.723.916 6.48%
2019 1.658.916 -3.92%
2020 946.128 -75.34%
2021 894.981 -5.71%
2022 680.144 -31.59%
2023 644.920 -5.46%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Aquarius Surgical Technologies Inc. Liabilities
Year Liabilities Growth
1996 2.900.000
1997 5.600.000 48.21%
1998 6.300.000 11.11%
1999 7.200.000 12.5%
2000 7.983.476 9.81%
2001 2.842.395 -180.87%
2002 2.778.842 -2.29%
2003 3.043.535 8.7%
2004 3.365.214 9.56%
2005 2.101.967 -60.1%
2006 2.188.705 3.96%
2007 2.535.023 13.66%
2008 2.963.575 14.46%
2009 3.342.317 11.33%
2010 3.574.103 6.49%
2011 3.804.450 6.05%
2012 4.104.797 7.32%
2013 3.883.542 -5.7%
2014 4.055.410 4.24%
2015 3.876.473 -4.62%
2016 3.381.517 -14.64%
2017 1.483.515 -127.94%
2018 2.177.812 31.88%
2019 2.348.071 7.25%
2020 3.340.788 29.72%
2021 4.109.837 18.71%
2022 4.528.040 9.24%
2023 4.846.305 6.57%

Aquarius Surgical Technologies Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.03
Price to Earning Ratio
-0.19x
Price To Sales Ratio
0.73x
POCF Ratio
-0.58
PFCF Ratio
-0.57
Price to Book Ratio
-0.03
EV to Sales
19.95
EV Over EBITDA
-6.32
EV to Operating CashFlow
-15.91
EV to FreeCashFlow
-15.63
Earnings Yield
-5.21
FreeCashFlow Yield
-1.76
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.3
Graham NetNet
-0.17

Income Statement Metrics

Net Income per Share
-0.03
Income Quality
0.33
ROE
0.18
Return On Assets
-1.02
Return On Capital Employed
0.44
Net Income per EBT
0.98
EBT Per Ebit
1.21
Ebit per Revenue
-2.59
Effective Tax Rate
-0.05

Margins

Sales, General, & Administrative to Revenue
2.28
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.06
Gross Profit Margin
0.58
Operating Profit Margin
-2.59
Pretax Profit Margin
-3.14
Net Profit Margin
-3.09

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0.02
Capex to Revenue
-0.02
Capex to Depreciation
-0.2
Return on Invested Capital
1.97
Return on Tangible Assets
-1.11
Days Sales Outstanding
165.41
Days Payables Outstanding
0
Days of Inventory on Hand
106.57
Receivables Turnover
2.21
Payables Turnover
0
Inventory Turnover
3.42
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,15
Tangible Book Value per Share
-0.15
Shareholders Equity per Share
-0.15
Interest Debt per Share
0.14
Debt to Equity
-0.9
Debt to Assets
5.85
Net Debt to EBITDA
-6.09
Current Ratio
0.14
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-0.9
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
26468
Debt to Market Cap
27.33

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Aquarius Surgical Technologies Inc. Dividends
Year Dividends Growth

Aquarius Surgical Technologies Inc. Profile

About Aquarius Surgical Technologies Inc.

Aquarius Surgical Technologies Inc., through its subsidiary, Surgical Lasers Inc., develops, sells, distributes, and markets technologies for use in surgical and other environments in Canada and the United States. It offers medical laser solutions across multiple medical disciplines, including urology, gynecology, ophthalmology, thoracic, ENT, cardiovascular, and neurosurgery. The company was formerly known as Aquarius Coatings Inc. Aquarius Surgical Technologies Inc. was incorporated in 1986 and is based in Toronto, Canada.

CEO
Mr. Lorne Stewart MacFarlane
Employee
0
Address
89 Scollard Street
Toronto, M5R 1G4

Aquarius Surgical Technologies Inc. Executives & BODs

Aquarius Surgical Technologies Inc. Executives & BODs
# Name Age
1 Mr. Christopher H. Freeman
Secretary
70
2 Mr. Lorne Stewart MacFarlane
Chief Financial Officer
70

Aquarius Surgical Technologies Inc. Competitors